Amicus Therapeutics (FOLD) News Today $7.50 -0.50 (-6.25%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$7.66 +0.16 (+2.15%) As of 04/4/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Trexquant Investment LP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Trexquant Investment LP boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 966,049 shares of the biopharmaceutical company's stock after acquiring anApril 4 at 5:21 AM | marketbeat.comQ1 EPS Estimate for Amicus Therapeutics Boosted by AnalystApril 4 at 2:25 AM | americanbankingnews.comAnalysts Set Expectations for FOLD Q1 EarningsApril 4 at 1:35 AM | americanbankingnews.comZacks Research Issues Optimistic Estimate for FOLD EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for Amicus Therapeutics in a research report issued to clients and investors on Tuesday, April 1st. Zacks Research analyst R. Department now expeApril 3 at 6:18 AM | marketbeat.comWellington Management Group LLP Buys 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wellington Management Group LLP boosted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,461,994 shares of the biopharmaceutical compaApril 3 at 5:04 AM | marketbeat.comPictet Asset Management Holding SA Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Pictet Asset Management Holding SA reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,April 3 at 4:18 AM | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.75 Consensus PT from AnalystsApril 3 at 2:09 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Hits New 12-Month Low - Time to Sell?Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month Low - Time to Sell?April 1, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have assigned aMarch 31, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year Low - Time to Sell?Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week Low - Should You Sell?March 26, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Should You Sell?Amicus Therapeutics (NASDAQ:FOLD) Stock Price Down 2.5% - Time to Sell?March 25, 2025 | marketbeat.comFox Run Management L.L.C. Has $589,000 Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Fox Run Management L.L.C. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 93.1% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 62,570 shares of the biopharmaceutical company's stock after acquiring an additional 30,1March 25, 2025 | marketbeat.comIntech Investment Management LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Intech Investment Management LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 59.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 124,704 shares of the biopharmaceutical company's stock afterMarch 23, 2025 | marketbeat.comSemanteon Capital Management LP Buys 43,288 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Semanteon Capital Management LP increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,156 shares of the biopMarch 22, 2025 | marketbeat.comPrimecap Management Co. CA Sells 94,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Primecap Management Co. CA decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 934,800 shares of the biopharMarch 21, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 86.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 174,397 shares of the biopharmaceutical company's stock after selling 1,083,811 sharMarch 19, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 3.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,586,803 shares of the biopharmaMarch 19, 2025 | marketbeat.comIs Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now?March 18, 2025 | msn.comConnor Clark & Lunn Investment Management Ltd. Increases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Connor Clark & Lunn Investment Management Ltd. lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 35.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 302,536 shares of the biopharmaceutical companMarch 18, 2025 | marketbeat.comAmicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)March 17, 2025 | seekingalpha.comGreat Lakes Advisors LLC Has $1.68 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Great Lakes Advisors LLC reduced its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 20.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 178,477 shares of the biopharmaceutical comMarch 16, 2025 | marketbeat.comAmicus Therapeutics, Inc. (FOLD): Among the Stocks Under $10 With High Upside PotentialMarch 12, 2025 | insidermonkey.comInceptionr LLC Sells 37,014 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Inceptionr LLC lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 72.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,778 shares of the biopharmaceutical company's stock after selling 37,014March 11, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year Low - Here's What HappenedAmicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year Low - Should You Sell?March 10, 2025 | marketbeat.comEssex Investment Management Co. LLC Sells 37,529 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Essex Investment Management Co. LLC trimmed its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 14.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 231,214 shares ofMarch 10, 2025 | marketbeat.comBalanced Outlook on Amicus Therapeutics Amid Growth Ambitions and Market ChallengesMarch 7, 2025 | tipranks.comIn NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal OfficerMarch 6, 2025 | globenewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Decrease in Short InterestAmicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 14,740,000 shares, a decline of 15.0% from the January 31st total of 17,340,000 shares. Based on an average daily volume of 2,350,000 shares, the days-to-cover ratio is presently 6.3 days.March 6, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have giMarch 6, 2025 | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency ActMarch 3, 2025 | globenewswire.comAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2025February 27, 2025 | globenewswire.comY Intercept Hong Kong Ltd Has $1.14 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Y Intercept Hong Kong Ltd increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 245.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 120,958 shares of the biopharmaceutical coFebruary 27, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by HealthInvest Partners ABHealthInvest Partners AB lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,840 shares of the biopharmaceutical companyFebruary 24, 2025 | marketbeat.comAmicus Therapeutics: Strategic Market Expansion and Robust Sales Drive Buy RatingFebruary 23, 2025 | tipranks.comState of New Jersey Common Pension Fund D Buys 50,236 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)State of New Jersey Common Pension Fund D increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 220,500 shares of the biopharmaceuFebruary 23, 2025 | marketbeat.comTranscend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Transcend Capital Advisors LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 363,913 shares of the biopharmaceutical comFebruary 22, 2025 | marketbeat.comAmicus Therapeutics CEO Campbell Bradley sells $4,000 in stockFebruary 21, 2025 | investing.comWells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00Wells Fargo & Company reduced their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday.February 21, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD)Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday.February 21, 2025 | marketbeat.comAmicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy ChangesFebruary 21, 2025 | tipranks.comAmicus price target lowered to $17 from $18 at Wells FargoFebruary 20, 2025 | markets.businessinsider.comAmicus Therapeutics CEO says biotech firm is on path to $1B in revenueFebruary 20, 2025 | bizjournals.comAmicus Therapeutics CEO says biotech firm is on path to $1B in revenueFebruary 20, 2025 | bizjournals.comAmicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 20, 2025 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 20, 2025 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call TranscriptFebruary 20, 2025 | msn.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call TranscriptFebruary 20, 2025 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing EarningsAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing EarningsFebruary 20, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPSAmicus Therapeutics (NASDAQ:FOLD - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Amicus Therapeutics had a negative return on equity of 15.97% and a negative net margin of 21.21%.February 20, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Lowered to "Hold" Rating by StockNews.comStockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday.February 20, 2025 | marketbeat.com Remove Ads Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼1.110.61▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼145▲FOLD Articles Average Week Remove Ads Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXAS News HALO News MDGL News RGEN News ALKS News IONS News LGND News DVAX News BCRX News MNKD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FOLD Stock Free FOLD Stock Alerts